The Priority Review

Tag

Intra-Cellular Therapies, Inc.

2 stories

Stories

  1. Clinical trials

    Intra-Cellular Therapies, Inc. posts results of Lumateperone schizophrenia relapse study

    The Phase 3 study enrolled 592 participants and was completed with primary completion on July 25, 2024. Results were first posted on ClinicalTrials.gov on October 5, 2026.

  2. Clinical trials

    Intra-Cellular Therapies registers JNJ-99245354 (ITI-1284) in generalized anxiety disorder

    This study was first posted on ClinicalTrials.gov on October 2, 2026. The trial plans to enroll 705 participants and has a planned start date of September 30, 2026, with a primary completion date of September 20, 2030.